Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CLVS

The 5 Most Active Stocks to Watch Right Now

As many economists are cutting down GDP forecasts for the second quarter, market uncertainties are expected to increase. Therefore, one could consider investing in stocks showing resiliency and trading at high volumes. Clovis Oncology (CLVS), Advanced Micro Devices (AMD), Roblox (RBLX), Ford Motor (F), and Marathon Digital (MARA) have been…

StockNews.com · Jul 12, 2022

Clovis Shares Jumps After Highlighting Data From Targeted Radiotherapy Trial

Clovis Oncology Inc (NASDAQ:CLVS) announced a presentation detailing initial Phase 1 data from Phase 1/2 LuMIERE clinical study of FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286). Overall, in nine patients treated in the first two dose cohorts, 177Lu-FAP-2286 demonstrated a manageable safety profile and encouraging evidence of activity, including a confirmed RECIST partial response in…

Benzinga · Jun 15, 2022

Clovis Oncology: Q1 Earnings Insights

Clovis Oncology (NASDAQ:CLVS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 4, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Clovis Oncology Targeted Cancer Radiation Therapy Shows Greater Tumor Inhibition

Clovis Oncology Inc (NASDAQ: CLVS) announced two abstracts featuring

Benzinga · Apr 8, 2022

Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status

Clovis Oncology Inc (NASDAQ:CLVS) announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca (Rucaparib) as first-line maintenance treatment in ovarian cancer. Rubraca achieved the primary endpoint of significantly improved progression-free survival (PFS) compared with placebo (20.2 months vs. 9.2 months). The median PFS for the HRD-positive patient…

Benzinga · Mar 31, 2022

Recap: Clovis Oncology Q4 Earnings

Clovis Oncology (NASDAQ:CLVS) reported its Q4 earnings results on Wednesday, February 23, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · Feb 23, 2022

Coverage From

Organisations

Advanced Micro Devices, Inc

Marathon Digital Holdings, Inc

30 stories

Lumiere

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.